Myriad Genetics Addresses Updated Policy by UnitedHealthcare
Myriad Genetics, Inc., a pioneering leader in the fields of genetic testing and precision medicine, has recently responded to an updated policy by UnitedHealthcare regarding pharmacogenetic testing. Effective January 1, 2025, this new policy restricts access to multi-gene panel tests, including the highly regarded GeneSight test, which aims to improve medication management in patients dealing with mental health issues.
Concerns Over Coverage Changes
In their review of the updated medical policy, Myriad expressed strong disagreement with the rationale provided by UnitedHealthcare for its decision. The health insurer claims that there is insufficient evidence to support the coverage of GeneSight. Myriad Genesis firmly believes in the extensive clinical evidence backing their GeneSight test, a tool specifically designed to assist healthcare professionals in determining the most effective medications for patients with mental health needs.
Importance of GeneSight Testing
Paul J. Diaz, President and CEO of Myriad Genetics, voiced his disappointment at UnitedHealthcare's actions, stating, "The clinical validity and utility of GeneSight have been demonstrated through a significant body of research, including peer-reviewed studies." He highlighted that in light of the ongoing mental health crisis, more than 70% of antidepressant prescriptions are made in primary care settings. The demand for GeneSight reflects its critical role in ensuring patients find appropriate treatment methods, especially for conditions such as depression and anxiety.
Impact of Policy Shift on Accessibility
Despite the concerning restrictions under UnitedHealthcare's new policy, Myriad Genetics anticipates that coverage for GeneSight will remain available to individuals under Medicare Advantage and managed Medicaid plans. The company is optimistic because several other health plans have recently issued favorable coverage determinations, validating the clinical utility of GeneSight as well as applicable state legislation regarding biomarkers.
Looking Ahead: Informative Earnings Call
Myriad is set to hold an earnings conference call soon, where they will elaborate on their discussions with UnitedHealthcare and discuss any potential financial impacts resulting from the recent policy changes. This engagement with UnitedHealthcare underscores Myriad's commitment to ensuring continual access to their essential testing services.
Understanding the GeneSight Test
Myriad Genetics has established the GeneSight Psychotropic test as a frontrunner in pharmacogenomics, assessing the workings of over 60 medications frequently prescribed for psychiatric conditions. By utilizing the test, healthcare providers can better understand how patients metabolize these medications, leading to more tailored and effective treatment plans. The broad adoption of GeneSight underscores its significance as a valuable resource for clinicians, enhancing patient care by minimizing the reliance on trial-and-error approaches in medication selection.
About Myriad Genetics
Myriad Genetics stands out as a leading entity in genetic testing and precision medicine dedicated to improving global health. The company develops and markets a variety of tests designed to evaluate disease risk and inform treatment paths, demonstrating how genetic insights can significantly enhance patient care while also addressing healthcare costs.
Frequently Asked Questions
What is the updated policy by UnitedHealthcare regarding GeneSight?
UnitedHealthcare's updated policy restricts access to multi-gene panel pharmacogenetic tests, including GeneSight, based on claims of insufficient evidence.
How does Myriad Genetics respond to this policy change?
Myriad has expressed strong disagreement with the decision, citing extensive clinical evidence supporting the effectiveness of the GeneSight test.
What does the GeneSight test do?
The GeneSight test provides insights into how a patient's genetics may affect their response to psychiatric medications, helping tailor treatment plans for conditions like depression and anxiety.
Will coverage for GeneSight change for Medicare Advantage and Medicaid plans?
No, Myriad believes that Medicare Advantage and managed Medicaid plans will continue to cover GeneSight testing despite the changes implemented by UnitedHealthcare.
How is Myriad Genetics addressing this issue with UnitedHealthcare?
Myriad is engaging with UnitedHealthcare to advocate for continued access to GeneSight, emphasizing its clinical validity and contributions to mental health treatment.
